Siemens Healthineers on Tuesday reported that its revenues rose about 2 percent on a reported basis and 3 percent on a comparable basis during its fiscal second quarter on rising sales of its non-COVID diagnostics products and its advanced therapies products.

Biochemical diagnostic reagents, as one of the main categories of diagnostic reagents, are characterized by a large population coverage, a high proportion of services and service users and a huge market size.

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

On April 1, Mr. Yu Rong, Chairman of Meinian Onehealth, and his delegation visited the headquarter of Adicon to have a discussion and exchange views on the strategic cooperation and innovative business cooperation between Meinian Onehealth and Adicon.

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.

From April 17 to 26, 2024, Hesheng Wang, Vice Minister of the National Health Commission of the PRC and Director of the National Disease Control and Prevention Administration, led a delegation to visit Germany, Finland and the Republic of Korea.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the first quarter of 2024.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024.

The US Food and Drug Administration released on Monday its final rule to regulate laboratory-developed tests (LDTs).

The fully automatic biochemistry analyzer, characterized by high technical content, high accuracy, high precision, high flexibility, and high working efficiency, has become one of the indispensable instruments in the modern clinical laboratory for the increasing testing work.

Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies.

The European Parliament has agreed to adopt measures to delay certain deadlines of the In Vitro Diagnostic Medical Devices Regulation (IVDR) and to gradually roll out the European Database on Medical Devices (Eudamed), the European Commission said on Thursday.